BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16609060)

  • 1. Chemotherapy and targeted therapy combinations in advanced melanoma.
    Flaherty KT
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic chemotherapy.
    Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
    Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets in melanoma from angiogenesis to apoptosis.
    Sosman JA; Puzanov I
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of metastatic melanoma.
    Tawbi HA; Kirkwood JM
    Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for metastatic melanoma: time for a change?
    Gogas HJ; Kirkwood JM; Sondak VK
    Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and biologic therapies for melanoma: do they work?
    Jilaveanu LB; Aziz SA; Kluger HM
    Clin Dermatol; 2009; 27(6):614-25. PubMed ID: 19880049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
    Hartmann JT
    Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
    Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
    Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combinations based on epidermal growth factor receptor inhibition.
    Adjei AA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted molecular therapy in melanoma.
    Puzanov I; Flaherty KT
    Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.